Immunotherapy targeting programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 has demonstrated marked efficacy in mismatch repair‐deficient (dMMR) and MSI‐H colorectal cancers [6]. Here, PDCD1 is linked to colorectal cancer.